Depo Provera Safety in Patients with Neuro Tumors

Risk Assessment Based on Tumor Type

The American College of Medical Genetics and Genomics recommends that Depo Provera (medroxyprogesterone acetate) should generally be avoided in individuals with a history of neurofibromas or meningiomas due to evidence suggesting it may stimulate tumor growth, particularly when administered as a high-dose depot injection 1
Expression of progesterone receptors has been found in 75% of neurofibromas, making them potentially responsive to hormonal stimulation, according to the Genetics in Medicine journal 1
A survey of 59 women with Neurofibromatosis Type 1 (NF1) found that 2 patients (3%) who received depot contraceptives containing high doses of synthetic progesterone reported significant tumor growth, as reported in the Genetics in Medicine journal 1

The American Academy of Allergy and Clinical Immunology suggests that Intrauterine devices (IUDs) are well-tolerated by 83.3% of patients with neurofibromatosis, and the progesterone-eluting IUD (Mirena) could be beneficial for patients with NF1 at lower doses than injectable forms 2
Oral contraceptives do not seem to stimulate the growth of neurofibromas in most NF1 patients, according to the Genetics in Medicine journal 1

Regular monitoring for changes in existing tumors or development of new tumors is essential for patients already using Depo Provera, as recommended by the National Comprehensive Cancer Network (NCCN) 1, 3
For patients with NF1, assessment should include questions about signs and symptoms of tumor growth at each visit, according to the Genetics in Medicine journal 1
Patients with a history of neuroblastoma require personalized survivorship care plans that address potential late effects of treatment, as recommended by the National Comprehensive Cancer Network (NCCN) 3, 4

The prevention of unintended pregnancy is important, and the benefits of contraception may outweigh theoretical concerns in many cases, according to the Genetics in Medicine journal 1
Alternative contraceptive methods should be discussed with patients who have a history of neuro tumors, particularly those with documented progesterone receptor-positive tumors, as recommended by the Genetics in Medicine journal 1
For patients with epilepsy related to brain tumors who require contraception, drug interactions between anticonvulsants and hormonal contraceptives should be considered, as reported in the Neuro-Oncology journal 5

Assuming all hormonal contraceptives carry equal risk for patients with neuro tumors; depot formulations appear to pose greater risk than oral or IUD options, according to the Genetics in Medicine journal 1
Not discussing the potential delayed return to fertility (9-18 months) after discontinuation of Depo Provera, which is an important consideration for cancer survivors planning families, as reported in the Pediatrics journal 6